Search our Current Studies

Still have some questions about the process? Review our Frequently Asked Questions for the answers.
Learn More
Image

Long-term Evaluation of Safety and Performance of Clareon Presbyopia-Correcting Intraocular Lenses (IOLs)

Location(s): Jacksonville - Florida Eye Specialist (Gate)

Condition: Cataract

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

Location(s): Macon

Condition: Type 2 Diabetes

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia

Location(s): Macon

Condition: Heart / Cardiovascular Disease, High Cholesterol

A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD

Location(s): St. Augustine

Condition: Heart / Cardiovascular Disease, Kidney Disease, Overweight / Obesity

A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation

Location(s): Jacksonville (Headquarters)

Condition: Atrial Fibrillation

A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus

Location(s): Jacksonville (Headquarters), Jacksonville - Southside

Condition: Overweight / Obesity, Type 2 Diabetes

A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 Diabetes

Location(s): Jacksonville (Headquarters), Jacksonville - Southside

Condition: Overweight / Obesity

Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)

Location(s): Jefferson City

Condition: Heart / Cardiovascular Disease

Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Jacksonville - Southside, Lake City, St. Augustine

Condition: Heart / Cardiovascular Disease, High Cholesterol

Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

Location(s): Jacksonville (Headquarters), Jacksonville - Southside, Lake City, Macon, St. Augustine

Condition: Heart / Cardiovascular Disease, High Cholesterol

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

Location(s): Jacksonville (Headquarters), Jacksonville - Southside

Condition: Overweight / Obesity, Type 2 Diabetes

IMPACT2: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2 – Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes

Location(s): Canton, Jacksonville - LaVilla (Downtown), Macon

Condition: Type 2 Diabetes

A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Jacksonville - Southside, Lake City, Macon, St. Augustine

Condition: Heart / Cardiovascular Disease

A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)

Location(s): St. Augustine

Condition: Peripheral Vascular Disease

A Non-Interventional Study to Evaluate the Effect of Intraocular Lens (IOL) Centration and Tilt on Visual Performance in Patients Who Have Undergone Clareon® Vivity® IOL Implantation

Location(s): Jacksonville - Florida Eye Specialist (Gate)

Condition: Cataract, Eye Disease

Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation

Location(s): Jacksonville (Headquarters)

Condition: Heart / Cardiovascular Disease, Kidney Disease

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Location(s): Macon

Condition: Overweight / Obesity, Type 2 Diabetes

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Location(s): Jacksonville - Florida Eye Specialist (Gate)

Condition: Ocular Hypertension, Open-Angle Glaucoma

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

Location(s): Jacksonville (Headquarters), St. Augustine

Condition: Heart Failure

A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)

Location(s): Jacksonville - Florida Eye Specialist (Gate)

Condition: Eye Disease, Ocular Hypertension, Open-Angle Glaucoma